Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2025 Mar 31, 13:42

Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution

Vir Biotechnology Inc
Webhose 2025 Mar 31, 00:00

Authority Investment Dhabi Abu - Insider Monkey

Vir Biotechnology Inc
Webhose 2025 Mar 30, 10:13

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts

Vir Biotechnology Inc
Webhose 2025 Mar 30, 08:59

Artisan Partners Limited Partnership Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2025 Mar 30, 08:26

WINTON GROUP Ltd Reduces Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2025 Mar 29, 00:52

Vir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low - Here's Why

Vir Biotechnology Inc
Webhose 2025 Mar 28, 12:24

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company

Vir Biotechnology Inc
Webhose 2025 Mar 27, 08:41

Fox Run Management L.L.C. Takes $364,000 Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2025 Mar 27, 08:32

49,651 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Fox Run Management L.L.C.

Vir Biotechnology Inc
Webhose 2025 Mar 23, 07:10

Vir Biotechnology, Inc. (NASDAQ:VIR) Holdings Raised by Charles Schwab Investment Management Inc.

Vir Biotechnology Inc
Webhose 2025 Mar 19, 07:06

Bank of New York Mellon Corp Lowers Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2025 Mar 13, 12:11

Vir Biotechnology enrolls first patient in ECLIPSE program | Markets Insider

Vir Biotechnology Inc
Webhose 2025 Mar 11, 07:34

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $35.67 Consensus Target Price from Analysts

Vir Biotechnology Inc
Webhose 2025 Mar 06, 00:00

Hepatitis B Virus Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies | ABNewswire

Vir Biotechnology Inc
Webhose 2025 Mar 05, 08:16

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund

Vir Biotechnology Inc

Latest news

Frances Wang 2025 Apr 02, 16:00

USD/JPY Forecast: Analyzing Market Trends and Economic Indicators

Forex
Tommy Yap 2025 Apr 02, 16:00

Morning Note: U.S. Tariffs Shake Markets, Nikkei Sinks & Swiss Inflation Data Awaits

Morning Note USD
Frances Wang 2025 Apr 01, 16:00

Silver news today: Why has the silver price been volatile recently?

Commodities
three barrels of oil, neftechka, and American dollars against the background of a wooden table
Tommy Yap 2025 Mar 31, 21:00

Morning Note: US Jobs Data, Oil Steady on Tariffs, MicroStrategy BTC Bet

Oil Morning Note Cryptocurrencies
Frances Wang 2025 Mar 31, 16:00

Gold Prices Hit New Highs: What is Gold CFD trading?

Commodities
Frances Wang 2025 Mar 31, 16:00

Oil Markets Today: Oil Falls on OPEC+ Output Hike and Trump’s Tariffs

Commodities
Japan retail 
Tommy Yap 2025 Mar 29, 21:00

Morning Note: Japan Retail, China PMI, Germany Inflation

Japan Morning Note China
Tommy Yap 2025 Mar 29, 16:00

Week Ahead: U.S. Non-Farm Payrolls Coming Up: What to Expect

Forex Indices

Info

Spread

0.05

Spread (%)

0.7764 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Thursday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

847543744

Shares Outstanding

137143008

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.83

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments
Trustpilot